1 insider has bought $288k of Immunome Inc. shares across 3 disclosed dealings since May 2026. 2 of those have been scored against our six-point signal check.
| Jun 5, 2026 | BIENAIME JEAN JACQUES — director | $68,110 |
| Jun 5, 2026 | BIENAIME JEAN JACQUES — director | $116,880 |
| May 15, 2026 | BIENAIME JEAN JACQUES — director | $103,500 |
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including IM-3050, a fibroblast activation protein targeted radioligand therapy; and solid tumor ADC drug candidates, such as IM-1617, IM-1340, and IM-1335. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.